Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

AstraZeneca's Medimmune subsidiary announced a collaboration this morning with UK company Immunocore that will focus on the development of cancer therapeutics.

The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to tackle tumours.

The deal potentially covers a number of targets, with AZ offering an upfront fee of $20m and up to $300m in development and milestone payments per programme, plus royalties if any of the therapies reach the market.

Immunocore also has collaborations in place with GlaxoSmithKline and Roche/Genentech, as well as its own melanoma therapy in phase II testing.

Article by
Phil Taylor

9th January 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics